| 良性前列腺增生症的药物治疗及个体化用药 |
| 投稿时间：2016-11-08 修订日期：2017-03-13 点此下载全文 |
| 引用本文：雷永芳,凌青.良性前列腺增生症的药物治疗及个体化用药[J].药学实践杂志,2017,35(5):447~448,456 |
| 摘要点击次数: 1681 |
| 全文下载次数: 1394 |
|
| 基金项目:国家自然科学基金项目（81603177） |
|
| 中文摘要:目的 对良性前列腺增生症（BPH）药物治疗中的困境作初步探讨，以期为临床个体化用药的选择提供参考。方法 分析BPH常用药物和一些新型药物的作用机制及存在的问题。结果 BPH的治疗以α-受体抑制剂和5α-还原酶抑制剂效果最好，然而并不是所有患者都对药物治疗敏感，还有一些患者需要手术。结论 在药物的选择过程中尽量采用个体化用药方案，在减少医疗资源浪费的同时也能为患者提供最佳的治疗方式。 |
| 中文关键词:良性前列腺增生症 药物治疗 个体化用药 |
| |
| Drug therapy for benign prostatic hyperplasia and individualized drug regime |
|
|
| Abstract:Objective To review the drug therapies for benign prostatic hyperplasia (BPH) and provide a reference for clinical individualized medication regime. Methods The mechanisms and clinical indications of commonly used BPH medications and some new drugs were discussed. The challenges for BPH therapies were also explored. Results α-receptor inhibitors and 5α-reductase inhibitors have the best effect for BPH. Surgery is needed for the BPH patients who are not responsive to the drug therapy. Conclusion Individualized medication programs reduce the medication waste and give patients the best treatment options. |
| keywords:benign prostatic hyperplasia (BPH) drug therapy personalized medicine |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
